Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2012

View Archived Issues

Phase I/II and phase II gene therapy trials conducted in patients with SCID

S1P1 receptor agonist shows efficacy in preclinical models of IBD

French researchers present new HSP 90 inhibitors

Eisai presents highlights of fiscal 2011

Novel candidate analgesic patented

Early clinical results presented for tralokinumab in asthma

A new small molecule inhibits dermal inflammation in mouse models

Human pharmacokinetic profile of RO-5458640 determined in monkeys

BMS investigators describe preclinical studies with antimigraine candidate

Phase I/II Xerecept results promising in children with cerebral tumors

Research at Presidio Pharmaceuticals yields new HCV inhibitors

U.S. government supports phase III smallpox vaccine study

Karolinska University Hospital and GE Healthcare enter research collaboration

Phase III HA-irinotecan study to continue enrollment

Novel imaging agents created to diagnose Alzheimer's disease

New AP-TNAP inhibitors presented in France

Catalyst reports topline data from phase Ia CPP-115 study

Unigene reports encouraging preclinical data on UGP-281

Novel ER-alpha agonists patented

FDA approves expanded use of Levemir

Chelsea Therapeutics discusses Northera complete response letter with FDA

Repros submits revised documentation to FDA for Androxal studies

NICE publishes guidance on rivaroxaban

Adva-27a shows superior pharmacokinetic profile than etoposide

Confirmatory U.S. phase III trial of Scenesse begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...